Phase II trial of mTORC1/mTORC2 inhibitor AZD2014 for sporadic meningioma

Project: Research project

Project Details


In this study, patients with recurrent or progressive grade 2 and 3 meningiomas will be enrolled for treatment with the dual mTORC1/mTORC2 inhibitor, AZD2014. We plan to recruit a total of 15 patients in years 2, 3 and 4. We have an extremely busy neuro-oncology program at Northwestern Memorial Hospital with multiple active clinical trials. Currently, we do not have any ongoing trials for recurrent meningioma, and this trial would be of great interest for our patients with recurrent meningiomas for which they are little treatment options. We will gladly enroll eligible patients to this study, should it be funded.
Effective start/end date8/10/167/31/22


  • Massachusetts General Hospital (229149 AZD2014 // 5R01CA201130-04)
  • National Cancer Institute (229149 AZD2014 // 5R01CA201130-04)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.